Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt 1.43
OREX's Cash to Debt is ranked higher than
70% of the 910 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.48 vs. OREX: 1.43 )
OREX' s 10-Year Cash to Debt Range
Min: 1.43   Max: No Debt
Current: 1.43

Equity to Asset 0.11
OREX's Equity to Asset is ranked lower than
54% of the 823 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.59 vs. OREX: 0.11 )
OREX' s 10-Year Equity to Asset Range
Min: -3.15   Max: 0.86
Current: 0.11

-3.15
0.86
F-Score: 3
Z-Score: -1.71
M-Score: 5.54
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -161.16
OREX's Operating margin (%) is ranked higher than
50% of the 861 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 10.67 vs. OREX: -161.16 )
OREX' s 10-Year Operating margin (%) Range
Min: -107754.55   Max: -633.85
Current: -161.16

-107754.55
-633.85
Net-margin (%) -178.34
OREX's Net-margin (%) is ranked lower than
51% of the 861 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.48 vs. OREX: -178.34 )
OREX' s 10-Year Net-margin (%) Range
Min: -105954.55   Max: -637.83
Current: -178.34

-105954.55
-637.83
ROE (%) -273.78
OREX's ROE (%) is ranked lower than
55% of the 882 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.84 vs. OREX: -273.78 )
OREX' s 10-Year ROE (%) Range
Min: -235.61   Max: -42.04
Current: -273.78

-235.61
-42.04
ROA (%) -41.44
OREX's ROA (%) is ranked higher than
51% of the 914 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.19 vs. OREX: -41.44 )
OREX' s 10-Year ROA (%) Range
Min: -879.2   Max: -22.76
Current: -41.44

-879.2
-22.76
ROC (Joel Greenblatt) (%) -1728.52
OREX's ROC (Joel Greenblatt) (%) is ranked lower than
51% of the 908 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 15.66 vs. OREX: -1728.52 )
OREX' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -193375   Max: -3874.08
Current: -1728.52

-193375
-3874.08
Revenue Growth (3Y)(%) 10.10
OREX's Revenue Growth (3Y)(%) is ranked higher than
78% of the 743 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.60 vs. OREX: 10.10 )
OREX' s 10-Year Revenue Growth (3Y)(%) Range
Min: 0   Max: 10.1
Current: 10.1

0
10.1
EBITDA Growth (3Y)(%) -9.20
OREX's EBITDA Growth (3Y)(%) is ranked higher than
60% of the 703 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.10 vs. OREX: -9.20 )
OREX' s 10-Year EBITDA Growth (3Y)(%) Range
Min: 0   Max: -8
Current: -9.2

EPS Growth (3Y)(%) -10.10
OREX's EPS Growth (3Y)(%) is ranked higher than
65% of the 675 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.70 vs. OREX: -10.10 )
OREX' s 10-Year EPS Growth (3Y)(%) Range
Min: -55.4   Max: 153.4
Current: -10.1

-55.4
153.4
» OREX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2013

OREX Guru Trades in Q4 2013

Paul Tudor Jones 11,920 sh (New)
Steven Cohen 3,998,545 sh (+469.19%)
RS Investment Management 1,930,285 sh (+28.19%)
Steven Cohen 200,000 sh (unchged)
Steven Cohen 100,000 sh (unchged)
John Burbank Sold Out
» More
Q1 2014

OREX Guru Trades in Q1 2014

RS Investment Management 2,223,585 sh (+15.19%)
Paul Tudor Jones Sold Out
Steven Cohen 676,800 sh (-83.07%)
» More
Q2 2014

OREX Guru Trades in Q2 2014

RS Investment Management 2,179,142 sh (-2%)
» More
Q3 2014

OREX Guru Trades in Q3 2014

RS Investment Management 2,229,642 sh (+2.32%)
» More
» Details

Insider Trades

Latest Guru Trades with OREX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
John Burbank 2013-12-31 Sold Out 0.15%$4.72 - $6.83 $ 5.987%0
John Burbank 2012-09-30 New Buy0.2%$3.77 - $7.39 $ 5.9812%750000
George Soros 2012-06-30 Sold Out 0.03%$3.16 - $6.37 $ 5.9859%0
George Soros 2012-03-31 New Buy0.03%$1.68 - $5.01 $ 5.9892%500000
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 42.00
OREX's P/B is ranked lower than
51% of the 949 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.53 vs. OREX: 42.00 )
OREX' s 10-Year P/B Range
Min: 0.85   Max: 45.21
Current: 42

0.85
45.21
P/S 21.80
OREX's P/S is ranked higher than
55% of the 949 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.89 vs. OREX: 21.80 )
OREX' s 10-Year P/S Range
Min: 12.7   Max: 1495
Current: 21.8

12.7
1495
EV-to-EBIT -13.01
OREX's EV-to-EBIT is ranked higher than
63% of the 949 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 33.22 vs. OREX: -13.01 )
OREX' s 10-Year EV-to-EBIT Range
Min: -14.6   Max: 2.5
Current: -13.01

-14.6
2.5
Current Ratio 7.05
OREX's Current Ratio is ranked higher than
90% of the 893 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.41 vs. OREX: 7.05 )
OREX' s 10-Year Current Ratio Range
Min: 1.99   Max: 19.3
Current: 7.05

1.99
19.3
Quick Ratio 7.01
OREX's Quick Ratio is ranked higher than
91% of the 892 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.81 vs. OREX: 7.01 )
OREX' s 10-Year Quick Ratio Range
Min: 1.99   Max: 19.3
Current: 7.01

1.99
19.3

Valuation & Return

vs
industry
vs
history
Price/Net Current Asset Value 149.50
OREX's Price/Net Current Asset Value is ranked higher than
76% of the 949 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9999.00 vs. OREX: 149.50 )
OREX' s 10-Year Price/Net Current Asset Value Range
Min: 1.01   Max: 106.5
Current: 149.5

1.01
106.5
Price/Tangible Book 42.72
OREX's Price/Tangible Book is ranked higher than
54% of the 949 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.24 vs. OREX: 42.72 )
OREX' s 10-Year Price/Tangible Book Range
Min: 0.99   Max: 34.21
Current: 42.72

0.99
34.21
Price/Median PS Value 0.13
OREX's Price/Median PS Value is ranked higher than
99% of the 949 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.29 vs. OREX: 0.13 )
OREX' s 10-Year Price/Median PS Value Range
Min: 0.09   Max: 8.19
Current: 0.13

0.09
8.19
Earnings Yield (Greenblatt) -7.90
OREX's Earnings Yield (Greenblatt) is ranked higher than
53% of the 907 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.20 vs. OREX: -7.90 )
OREX' s 10-Year Earnings Yield (Greenblatt) Range
Min: 40.3   Max: 3901
Current: -7.9

40.3
3901

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare:TKPYY, TEVA, AGN, FRX, MRX » details
Traded in other countries:JXS.Germany,
Orexigen Therapeutics Inc was incorporated in Delaware in September 2002. Company is a biopharmaceutical company focused on the development of pharmaceutical product candidates for the treatment of obesity. Its product candidates are NB32, which has completed Phase III clinical trials and which is currently being studied in a cardiovascular outcomes trial, and Empatic, which has completed Phase II clinical trials. Both NB32 and Empatic regulate appetite and energy expenditure through central nervous system activity. NB32 is a fixed dose combination of bupropion and naltrexone. Company develops its product candidates for large markets traditionally served by primary care physicians. In order to effectively promote NB32 to these physicians, in September 2010, it entered into a collaboration agreement with Takeda to develop and commercialize NB32 in the United States, Canada and Mexico. It maintains an aggressive intellectual property strategy, which includes patent and trademark filings in multiple jurisdictions including the United States and other commercially significant markets. It relies on a combination of in-licensed patent rights, its own patent rights, trademarks, trade secrets and know-how to protect NB32 and Empatic. Its products used in clinical trials have been produced by outside contractors under its supervision. Company competes with AstraZeneca, Athersys, Inc., Bristol-Myers Squibb, Norgine BV, Novo Nordisk A/S, among others.
» More Articles for OREX

Headlines

Articles On GuruFocus.com
Revisiting Arena, Orexigen, And VIVUS: Shareholders Can Recoup Their Losses By Invest In MannKind Aug 19 2014 
Weekly CEO Sells Highlight: Orexigen Therapeutics Inc, Gas Natural Inc, The Middleby Corporation, an Jul 15 2012 
Weekly CEO Sells Highlight: Gas Natural Inc, Encore Bancshares Inc, Staples Inc, and Orexigen Therap Jul 08 2012 
Arena Facing Increased Pressure from Peers Apr 23 2012 
Arena Could Dip If Lorcaserin Fails Again Apr 22 2012 
Vivus Could Rocket on Success of Qnexa Apr 13 2012 
Steve Cohen Bets On Orexigen Ahead of FDA Approval Jan 31 2011 
Orexigen Therapeutics Inc. Reports Operating Results (10-Q) Nov 04 2010 
Orexigen Therapeutics Inc. Reports Operating Results (10-Q) Aug 06 2010 
cooldecency99 note on OREX May 01 2010 

More From Our Partners
Novo Nordisk's Saxenda Gets FDA Nod, Launch in 1H15 - Analyst Blog Dec 24 2014 - ZACKS

More From Other Websites
FDA clears Novo Nordisk's weight loss drug Saxenda Dec 23 2014
New highs! The S&P 500 closes just below its prior record close... Dec 19 2014
OREXIGEN THERAPEUTICS, INC. Files SEC form 8-K, Other Events Dec 19 2014
Orexigen Therapeutics Gains On Diet Pill Nod From European Committee Dec 19 2014
Orexigen's 'Goldilocks' Weight-Loss Pill is Just Right for European Regulators Dec 19 2014
Orexigen's Mysimba™ (naltrexone HCl / bupropion HCl prolonged release) Receives Positive CHMP... Dec 19 2014
European regulators recommend approval of Orexigen's obesity pill Dec 19 2014
Orexigen's Mysimba™ (naltrexone HCl / bupropion HCl prolonged release) Receives Positive CHMP... Dec 19 2014
Six Biotech and Technology Stocks With Strong Technical Set-Ups Dec 18 2014
Bio-Twitter Sentiment Favors European Orexigen Obesity Pill Approval Dec 17 2014
Obesity Pill Upstart Orexigen Therapeutics Gaining on Rivals Dec 12 2014
These 4 Biotech Stocks Have Been On Fire Dec 08 2014
Why Orexigen Therapeutics (OREX) Stock Might be a Great Pick Dec 05 2014
Earnings Estimates Moving Higher for Orexigen (OREX): Time to Buy? Dec 03 2014
Orexigen Therapeutics to Present at the Piper Jaffray Healthcare Conference Nov 26 2014
Orexigen Therapeutics to Present at the Piper Jaffray Healthcare Conference Nov 26 2014
Orexigen Announces Allowance of New U.S. Patent for Contrave® (naltrexone HCl / bupropion HCl... Nov 21 2014
Orexigen Announces Allowance of New U.S. Patent for Contrave® (naltrexone HCl / bupropion HCl... Nov 21 2014
Is Orexigen Really Worth Over 50% More? Nov 19 2014
OREXIGEN THERAPEUTICS, INC. Financials Nov 18 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK